Effects of Rosiglitazone on Metabolic Parameters and Large Artery Sclerosis in Nondiabetic Patients with Metabolic Sydrome
SHEN Zhen-hai,LU Yun,JIN Xian,FENG Yin-bo
2010-01-01
Abstract:Objective To observe the effects of rosiglitazone on metabolic parameters,carotid intimamedia thickness( IMT) ,brachial-ankle pulse wave velocity( baPWV) and ankle-brachial index( ABI) in nondiabetic patients with metabolic syndrome. Methods Seventy-nine nondiabetic patients with metabolic syndrome were randomly divided into treatment group ( n = 41) and control group ( n = 38) . The patients in treatment group were treated with rosiglitazone on the basis of life-style intervention,those in control group were treated with life-style intervention for 9 months. All patients were followed up every 3 months. Body mass index ( BMI) ,waist circumference( WC) ,systolic blood pressure( SBP) ,diastolic blood pressure( DBP) ,fasting blood glucose ( FBG) ,triglyceride( TG) ,total cholesterol( TC) ,highdendity lipoprotein ( HDL-C) ,Low-density lipoprotein ( LDL) ,high sensitivity C-reactive protein ( hsCRP) ,HbA1C,fasting insulin( FIns) ,HOMA-IR,IMT,baPWV and ABI were measured in both groups before treatment and at the 6th,9th month after treatment. Results ( 1) After treatment with rosiglitazone for 6 months,FPG,TG,HDL-C,hsC RP,HbA1C,Fins and HOMA-IR in treatment group were improved ( P <0. 01) . FPG,HDL-C,hsC RP,HbA1C,Fins and HOMA-IR got further improvement at the 9th month after treatment( P < 0. 01) . After 9 months,FPG,HDL-C,hsC-RP,HbA1C,Fins and HOMA-IR were changed significantly in treatment group compared to those in control group( P < 0. 01) . ( 2) After treatment with rosiglitazone for 6 months,baPWV and ABI in treatment group were improved ( P < 0. 01) . IMT was not changed until the 9th month after treatment. IMT,baPWV,ABI were changed significantly in treatment group compared to those in control group after 9 months ( P < 0. 01) . ( 3) The reduction of HbA1C and HOMA-IR was independently related to the improvement of ABI by multivarient analysis. Conclusion In nondiabetic patients with metabolic syndrome,rosiglitazone can significantly improve insulin resistance,correct metabolic disorders,has anti-inflammatory effect and retard atherosclerosis at some extent.